1-9 of 9
Chao Zhang, PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase 1b Study of BET Inhibitor PLX2853 in Patients with Relapsed or Refractory Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome

Alice S. Mims, MD, Melhem Solh, MD, Uma Borate, Naveen Pemmaraju, MD, Gautam Borthakur, MD, Gail J. Roboz, MD, Ben Powell, PhD, Paul Severson, PhD, Bernice Matusow, Jason Halladay, PhD, Ching Hsu, PhD, Paul Watkins, Chao Zhang, PhD, Jackie M. Walling, PhD MD, Athanasios C. Tsiatis, MD, Amy E. DeZern, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 14–15.
https://doi.org/10.1182/blood-2020-140138
Published: 2020
Journal Articles

Robust Discovery of Candidate DNA Methylation Cancer Drivers

Heng Pan, PhD, Loïc Renaud, MD MSc, Ronan Chaligne, PhD, Johannes Bloehdorn, MD, Eugen Tausch, MD, Daniel Mertens, PhD, Anna-Maria Fink, MD, Kirsten Fischer, MD, Chao Zhang, PhD, Doron Betel, PhD, Andreas Gnirke, Marcin Imielinski, Jerome Moreaux, PhD, Michael Hallek, Alexander Meissner, PhD, Stephan Stilgenbauer, MD, Catherine J. Wu, MD, Olivier Elemento, PhD, Dan A. Landau, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 33–34.
https://doi.org/10.1182/blood-2020-136830
Published: 2020
Journal Articles

A Novel Combination Regimen of BET and FLT3 Inhibition for FLT3-ITD Acute Myeloid Leukemia

Lauren Lee, Yoshiyuki Hizukuri, Paul Severson, Ben Powell, PhD, Chao Zhang, PhD, Yan Ma, Maiko Narahara, Hiroyuki Sumi, PhD, Gideon Bollag, PhD, Mark J. Levis, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1373.
https://doi.org/10.1182/blood-2019-124030
Published: 2019
Journal Articles

Dose Escalation Study of BET Inhibitor PLX2853 in Patients with Relapsed or Refractory Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome

Naveen Pemmaraju, MD, Uma Borate, MD, Melhem Solh, MD, Gautam M. Borthakur, MD, Amy E. DeZern, MD, Chao Zhang, PhD, Ben Powell, PhD, Paul Severson, Kerry Inokuchi, Bernice Matusow, Jason Halladay, Ching Hsu, PhD, Paul Watkins, Jackie M. Walling, PhD MD, Athanasios C. Tsiatis, MD, Alice S. Mims, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1391.
https://doi.org/10.1182/blood-2019-127497
Published: 2019
Journal Articles

A Mixed Type 1 and Type 2 Kinase Inhibitor That Overrides FLT3 F691 and D835 Resistance Mutations

Jack Lin, PhD, Ying Zhang, PhD, Bernice Matusow, Adam Mumy, Garson Tsang, Jiazhong Zhang, PhD, Hannah Powers, Wayne Spevak, PhD, Paul Severson, PhD, James Tsai, Gideon Bollag, PhD, Chao Zhang, PhD
Journal: Blood
Blood (2016) 128 (22): 1074.
https://doi.org/10.1182/blood.V128.22.1074.1074
Published: 2016
Journal Articles

Biochemical and Functional Analysis of Novel KRAS Insertions in MPN and Other Cancers

Yasmine N White, Aditi Bagchi, Jessica Van Ziffle, PhD, Gideon Bollag, PhD, Chao Zhang, PhD, David S Dickens, MD, Mignon L. Loh, MD, Kevin Shannon, MD, Ari J Firestone, PhD
Journal: Blood
Blood (2014) 124 (21): 2207.
https://doi.org/10.1182/blood.V124.21.2207.2207
Published: 2014
Journal Articles

The Combination of PLX3397, a Selective FLT3-ITD Inhibitor, and Decitabine, a Hypomethylating Agent, Demonstrates Benefit in AML Cell Lines in Vitro and in Vivo

James Tsai, Elizabeth A Burton, PhD, Gaston Habets, PhD, Brian West, PhD, Paul Lin, MD, Henry Hsu, MD, Chao Zhang, PhD, Gideon Bollag, PhD
Journal: Blood
Blood (2014) 124 (21): 3743.
https://doi.org/10.1182/blood.V124.21.3743.3743
Published: 2014
Journal Articles

Preclinical and Clinical Resistance Mechanisms To The Investigational Selective FLT3 Inhibitor PLX3397 In FLT3-ITD+ Acute Myeloid Leukemia (AML)

Catherine C Smith, MD, Kimberly Lin, BS, Elisabeth Lasater, PhD, Whitney Stewart, BS, Lauren E Damon, Andrew Kasarskis, PhD, Ali Bashir, PhD, Matthew Pendleton, Robert Sebra, Alexander E Perl, MD, Mai H Le, MD, Chao Zhang, PhD, Brian West, Ph.D., Neil P. Shah, MD, PhD
Journal: Blood
Blood (2013) 122 (21): 3938.
https://doi.org/10.1182/blood.V122.21.3938.3938
Published: 2013
Journal Articles

PLX3397 Is An Investigational Selective FLT3 Inhibitor That Retains Activity Against the Clinically-Relevant FLT3-ITD/F691L “Gatekeeper” Mutation in Vitro

Catherine C. Smith, MD, Alexander E Perl, MD, Elisabeth Lasater, PhD, Chao Zhang, PhD, Grace R Jeschke, Lauren E. Damon, Martin Carroll, MD, Neil P. Shah, MD, PhD
Journal: Blood
Blood (2011) 118 (21): 764.
https://doi.org/10.1182/blood.V118.21.764.764
Published: 2011